Market Place
Sourcing Support
Roche Backs Amylin Drug for Low-Side-Effect Obesity Care
23 Apr 2026 //
BIOSPACE
Roche`s Breast Cancer Pill May Outsell Herceptin
23 Apr 2026 //
ENDPOINTS
Roche Exec: Giredestrant May Become Company`s Largest Product
23 Apr 2026 //
FIERCE PHARMA
Roche submits MS drug Fenebrutinib to Regulators Despite Patient
22 Apr 2026 //
REUTERS
Roche launches new Elevidys study after feedback from EU
16 Apr 2026 //
REUTERS
Roche Inaugurates Research Home for Institute of Human Biology
24 Mar 2026 //
INDPHARMAPOST
Roche Inaugurates Research Home for Institute of Human Biology
23 Mar 2026 //
GLOBENEWSWIRE
Roche Halts SMA Drug, Boosting Rivals` Prospects
20 Mar 2026 //
BIOSPACE
Genentech Shreds RIPK1 Inhibitor After Ph. 2 Failure
19 Mar 2026 //
FIERCE BIOTECH
Roche Launches NVIDIA AI Factory for Therapeutics, Diagnostics
17 Mar 2026 //
GLOBENEWSWIRE
Roche`s Oral SERD Flunks 1St-Line Breast Cancer Phase 3
10 Mar 2026 //
FIERCE BIOTECH
Genentech`s Gazyva Reduces Lupus Activity In Phase III Data
06 Mar 2026 //
PHARMIWEB
Roche Reports Positive Phase II Results For Petrelintide
05 Mar 2026 //
GLOBENEWSWIRE
Genentech Announces Positive Phase II Results for Petrelintide
05 Mar 2026 //
PHARMIWEB
Roche Pumps $480M Into South Korea Biopharma Industry
04 Mar 2026 //
FIERCE BIOTECH
North Carolina Attracts Amgen, Roche For Next-Gen Obesity Drug
03 Mar 2026 //
BIOSPACE
Emcure Partners with Roche on Nephrology, Transplant Care
03 Mar 2026 //
INDPHARMAPOST
Roche`s Fenebrutinib Validates First BTK Inhibitor For MS
03 Mar 2026 //
GLOBENEWSWIRE
Signatera MRD Data at ASCO GU Support Use Across GU Cancers
27 Feb 2026 //
BUSINESSWIRE
Volta Labs Launches New Products, Partnerships at AGBT 2026
26 Feb 2026 //
PR NEWSWIRE
FDA accepts NDA for Roche’s giredestrant in ESR1-Mutated
23 Feb 2026 //
GLOBENEWSWIRE
FDA Approves Venclexta, Acalabrutinib For Untreated CLL Leukemia
23 Feb 2026 //
PRESS RELEASE
Roche Announces Positive Phase III Results For Gazyva/Gazyvaro
17 Feb 2026 //
GLOBENEWSWIRE
Roche Unveils Data Behind BTK Inhibitor`s Phase 3 MS Win
09 Feb 2026 //
FIERCE BIOTECH
Roche`s Fenebrutinib Reduces Disability Progression In Primary
07 Feb 2026 //
GLOBENEWSWIRE
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
06 Feb 2026 //
FIERCE PHARMA
Roche Continues RNA Return With $1.7B Deal For Sanegene Drug
03 Feb 2026 //
FIERCE BIOTECH
JPM26, Day 1: Updates From Lilly, Takeda, Novartis And Sofinnova
12 Jan 2026 //
FIERCE BIOTECH
Roche Spends $570M On Another ADC Agreement With China`s Medilink
09 Jan 2026 //
BIOSPACE
Ollin Eyes Phase 3 After Topping Vabysmo In Early-Stage Trial
08 Jan 2026 //
FIERCE BIOTECH
FDA Approves Roche`s Lunsumio VELO For Subcutaneous Use
22 Dec 2025 //
GLOBENEWSWIRE
Natera and MEDSIR to Collaborate on the MiRaDoR Trial
12 Dec 2025 //
BUSINESSWIRE
Genentech`s Giredestrant Cuts Er-Positive Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
Roche Links SERD to 30% Breast Cancer Risk Reduction in Phase 3
10 Dec 2025 //
GLOBENEWSWIRE
Europe Approves Roche`s Gazyva For Active Lupus Nephritis
09 Dec 2025 //
GLOBENEWSWIRE
Roche Reveals Lunsumio Data Suggesting Promise In Early Lymphoma
08 Dec 2025 //
GLOBENEWSWIRE
Genentech Reveals Lunsumio Data In Early Lymphoma Treatment Lines
08 Dec 2025 //
BUSINESSWIRE
Roche`s Columvi Combo Demonstrates Long-Term Survival Benefit
08 Dec 2025 //
GLOBENEWSWIRE
Roche Reenters Alzheimer`s With New Antibody Clearing Amyloid
02 Dec 2025 //
BIOSPACE
Actinium Reveals ATNM-400`s Strong Efficacy in Breast Cancer
01 Dec 2025 //
PR NEWSWIRE
KaliVir & Roche Partner To Test VET3-TGI With Atezolizumab
19 Nov 2025 //
BUSINESSWIRE
European Commission Greenlights Roche`s Lunsumio Subcutaneous
19 Nov 2025 //
GLOBENEWSWIRE
Poherdy, First Biosimilar To Roche`s Perjeta, Scores FDA Nod
14 Nov 2025 //
FIERCE PHARMA
Eirgenix Signs Commercial Licensing Deal For HER2 Biosimilar
12 Nov 2025 //
PR NEWSWIRE
Roche`s Experimental MS Drug Hits Main Goal in One of Two Trial
09 Nov 2025 //
BUSINESSWIRE
Positive Phase III Data for Genentech’s Gazyva for Lupus
03 Nov 2025 //
BUSINESSWIRE
Roche To Unveil Innovative Hematology Data at ASH 2025
03 Nov 2025 //
GLOBENEWSWIRE
Roche`s Gazyva Tees Up Another Lupus Expansion With Phase 3 Win
03 Nov 2025 //
FIERCE PHARMA
Roche Pens $1B Deal For Respiratory Bispecific From China
30 Oct 2025 //
FIERCE BIOTECH
Roche`s Gazyva/Gazyvaro Shows Positive Phase III Results
28 Oct 2025 //
GLOBENEWSWIRE
Roche Pads Case For Gazyva In Immune-Mediated Kidney Conditions
28 Oct 2025 //
FIERCE PHARMA
Roche Axes 4 Chugai Solid Tumor Assets In Early-Phase Clear-Out
24 Oct 2025 //
FIERCE BIOTECH
Roche Unveils Positive Ph 3 Results For Vamikibart In UME Edema
22 Oct 2025 //
INDPHARMAPOST
Roche’s Gazyva Expands Out of Cancer With FDA Approval for Lupus
22 Oct 2025 //
BIOSPACE
Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer
21 Oct 2025 //
PRESS RELEASE
ESMO: The ADC `Rollercoaster` Rides On With Next-Gen Meds
21 Oct 2025 //
FIERCE BIOTECH
Genentech`s Tecentriq Demonstrates Major Survival Gains
20 Oct 2025 //
PHARMIWEB
EMPRESS Study Shows Giredestrant Cut Tumor Growth in Early Cancer
20 Oct 2025 //
PR NEWSWIRE
Roche Heads To FDA As Eye Disease Trials Yield Mixed Data
20 Oct 2025 //
FIERCE BIOTECH
ESMO: Merck Lays Out Keytruda`s Landmark Win In Ovarian Cancer
18 Oct 2025 //
FIERCE PHARMA
